SHOTW Safety Shot Inc

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C., 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 4, 2025

 

SAFETY SHOT, INC.

(Exact name of registrant as specified in charter)

 

Delaware		001-39569		83-2455880
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

 

1061 E. Indiantown Rd., Ste. 110, Jupiter, FL 33477

(Address of principal executive offices) (Zip Code)

 

(561) 244-7100

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		SHOT		The Nasdaq Stock Market LLC (The Nasdaq Capital Market)
Warrants, each exercisable for one share of Common Stock at $8.50 per share		SHOTW		The Nasdaq Stock Market LLC (The Nasdaq Capital Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 7.01 Regulation FD Disclosure

 

On March 4, 2025, Safety Shot, Inc. (the “Company”) issued a press release. A copy of the press release is furnished hereto as Exhibit 99.1 and incorporated herein by reference.

 

Exhibits 9.01 Financial Statements and Exhibits

 

Exhibit No.		Description
99.1		Press Release dated March 4, 2025
104		Cover Page Interactive Data File (embedded with the Inline XBRL document)

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: March 4, 2025

 

SAFETY SHOT, INC.
By:	/s/ Jarrett Boon
	Jarrett Boon,
	Chief Executive Officer

 

 

 

Exhibit 99.1

 

FOR IMMEDIATE RELEASE

 

Safety Shot Announces First Peer-Reviewed Publication of Human Clinical Trial Confirming Rapid Alcohol Reduction and Hangover Prevention

 

New controlled study published in Journal of Nutrition and Dietary Supplements highlights statistically significant reductions in ethanol levels following acute alcohol intake

 

SCOTTSDALE, Ariz., March 4, 2025 – Safety Shot, Inc. (Nasdaq: SHOT) (“Safety Shot” or the “Company”), a wellness and dietary supplement company, today announces the peer-reviewed publication of its groundbreaking randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy of Safety Shot® in mitigating the negative effects of alcohol consumption. The study, published in the Journal of Nutrition and Dietary Supplements (Feb 26, 2025, Volume 17, Pages 43-62), demonstrates that Safety Shot® statistically significantly reduces blood alcohol concentration (BAC), breath alcohol concentration (BrAC), and hangover symptoms compared to placebo (p < 0.05), and at a remarkably faster rate than the body’s natural processes. For the complete article, visit the website at: https://doi.org/10.2147/NDS.S507571

 

“This is a momentous occasion for Safety Shot as it demonstrates in a peer-reviewed setting, the potential for the product’s utility in daily practice. Alcohol consumption may have implications in multiple settings, but the results of this study show that there are solutions available – over the counter – that can mitigate its effects and dangers and allow for a more positive overall experience,” said Jarrett Boon, Safety Shot CEO. “Our unwavering commitment to scientific research and development has culminated in this groundbreaking achievement, and we believe that this clinically proven solution empowers individuals to take responsibility and control of their alcohol consumption.”

 

This is the first-ever human clinical trial to demonstrate the efficacy of a dietary supplement blend in reducing the acute effects of alcohol. Previous research has primarily relied on animal models, which may not translate directly into human physiology. Safety Shot’s human clinical trial provides more relevant and reliable data, positioning Safety Shot® as a revolutionary advancement in the field and a potential game-changer for the growing market of individuals seeking to manage the after-effects of alcohol consumption.

 

Details of the Trial

 

The study, conducted by The Center for Applied Health Sciences (CAHS), an independent, third-party research organization, involved healthy men and women of various ages, ethnicities and body types. Participants were randomly assigned to consume alcohol followed by either Safety Shot® or a placebo in a crossover design, where each participant served as their own control. This rigorous double-blind, randomized, placebo-controlled, crossover design ensured the highest level of scientific rigor and minimized inter-individual variability. Details include:

 

●

Rapid Alcohol Reduction: Safety Shot® reduced blood alcohol levels in as little as 30 minutes. This was evidenced by statistically significant reductions (p< 0.05) in both blood-drawn and breath-analyzed alcohol levels at 30 through 240 minutes after consumption.

 

 

	●	Rapid and Substantial Increase in Aldehyde Dehydrogenase: Over time, the aldehyde dehydrogenase values were significantly heightened. The AUC and Cmax for aldehyde dehydrogenase were both significantly greater in Safety Shot® vs Placebo (p = 0.004 and p = 0.010 respectively), suggesting an altering of the kinetics of acetaldehyde. By temporarily elevating acetaldehyde, Safety Shot effectively triggered a faster metabolic response, enhancing the body’s ability to eliminate alcohol and its toxic intermediates.
	●	Improved Hangover Symptoms: Trial participants taking Safety Shot® reported less head discomfort, reduced fatigue, increased energy levels, improvements in concentration, and reduced feelings of tiredness compared to the placebo. These improvements were observed at multiple time points throughout the study, as evidenced by the VAS scores.
	●	Increased Urine Output: Participants in the Safety Shot® group had greater urine output, particularly at the 60-minute mark, suggesting enhanced elimination of alcohol from the body.

 

Dr. Tim Ziegenfuss, CEO of CAHS, added, “These results are highly encouraging, showcasing Safety Shot’s potential as a beneficial supplement for individuals consuming alcohol. The observed reductions in breath and blood alcohol levels, along with the improvements in subjective feelings and physiological measures, highlight the benefit of Safety Shot in supporting better outcomes in post-alcohol consumption.”

 

The Company notes that given ethical and legal limitations, participants were only permitted to consume a small amount of alcohol. Further, study protocol was not limited to specific demographics as defined by age (except to be able to legally consume alcohol), sex, anthropometric disposition or frequency and tolerance of alcohol consumption. While many studies attempt to control for these variables, investigators made this as broad as possible to verify the potential for the widest use, and success, possible.

 

 

With these groundbreaking results, Safety Shot® is entering a massive and rapidly expanding global market for hangover cure products. According to a report by Grand View Research, this market is projected to grow at a compound annual growth rate (CAGR) of 14.1% from 2023 to 2030, reaching over $6 billion by 2032. This growth is fueled by increasing alcohol consumption, rising awareness of the negative health consequences of hangovers, and a growing desire for effective solutions. Safety Shot®, with its clinically proven efficacy and unique human-based research, is strategically positioned to capture a significant share of this burgeoning market.

 

About Safety Shot, Inc.

 

Safety Shot, Inc., a wellness and dietary supplement company, has developed Sure Shot, the first patented wellness product on Earth that lowers blood alcohol content by supporting its metabolism, while boosting clarity, energy, and overall mood. Sure Shot is available for purchase online at www.sureshot.com, www.walmart.com and Amazon. Safety Shot, Inc. is introducing business-to-business sales of Sure Shot to distributors, retailers, restaurants, and bars throughout 2025. Safety Shot® is a proprietary blend of natural ingredients, including red ginseng, N-acetyl cysteine, dandelion extract, milk thistle, and other antioxidants, anti-inflammatory agents, and nootropics. These ingredients work synergistically to support the body’s natural detoxification processes, reduce oxidative stress, and promote overall wellness.

 

Investor Relations:

 

CORE IR

516 222 2560

investors@drinksafetyshot.com

 

Media Contact:

CORE IR

Jules Abraham

516 222 2560

julesa@coreir.com

 

v3.25.0.1

Cover	Mar. 04, 2025
Document Type	8-K
Amendment Flag	false
Document Period End Date	Mar. 04, 2025
Entity File Number	001-39569
Entity Registrant Name	SAFETY SHOT, INC.
Entity Central Index Key	0001760903
Entity Tax Identification Number	83-2455880
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1061 E. Indiantown Rd.
Entity Address, Address Line Two	Ste. 110
Entity Address, City or Town	Jupiter
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33477
City Area Code	(561)
Local Phone Number	244-7100
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Information, Former Legal or Registered Name	Not Applicable
Common Stock [Member]
Title of 12(b) Security	Common Stock
Trading Symbol	SHOT
Security Exchange Name	NASDAQ
Warrants, each exercisable for one share of Common Stock at $8.50 per share
Title of 12(b) Security	Warrants, each exercisable for one share of Common Stock at $8.50 per share
Trading Symbol	SHOTW
Security Exchange Name	NASDAQ

---